Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Selective estrogen receptor modulators for BPH: new factors on the ground

Prostate Cancer and Prostatic Diseases volume 16, pages 226–232 (2013)Cite this article

Subjects

Abstract

As the current management of BPH/lower urinary tract symptoms by traditionally involved pharmacological agents such as 5alpha-reductase inhibitors and α1-adrenoceptor antagonists is suboptimal, there is definite need of new therapeutic strategies. There is ample evidence in literature that suggests the role of estrogens in BPH development and management through the different tissue and cell-specific receptors. This article reviews the beneficial actions of selective estrogen receptor modulator (SERM) and ERβ-selective ligands, which have been demonstrated through in vitro studies using human prostate cell lines and in vivo animal studies. SERMs have anti-proliferative, anti-inflammatory and pro-apoptotic mechanisms in BPH, and also act by inhibiting various growth factors, and thus represent a unique and novel approach in BPH management directed at estrogen receptors or estrogen metabolism.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Tang J, Yang J . Etiopathogenesis of benign prostatic hyperplasia. IJU 2009; 25: 312–331.

    PubMed  Google Scholar 

  2. Roehrborn CG . Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Medical Clin N Am 2011; 95: 87–100.

    Article  Google Scholar 

  3. Kumar R, Verma V, Sarswat A, Maikhuri JP, Dalela D, Gupta G et al. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms-action of two new agents. Invest New Drugs 2010; 30: 582–593.

    Article  CAS  PubMed  Google Scholar 

  4. Gray A, Feldman HA, McKinlay JB, Longcope C . Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metabol 1991; 73: 1016–1025.

    Article  CAS  Google Scholar 

  5. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR . Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metabol 2001; 86: 724–731.

    Article  CAS  Google Scholar 

  6. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I . Estradiol in elderly men. Aging Male 2002; 5: 98–102.

    Article  CAS  PubMed  Google Scholar 

  7. Vermeulen A . Testicular hormonal secretion and aging in males. In: Grayhack JT, Wilson JD, Scherbenske MJ (eds) Benign Prostatic Hyperplasia. Proceedings of Workshop Sponsored by the Kindney Disease and Urology Program of the NIAMDD, 20–21 February, 1975. US Government Printing office: Washington, DC, USA, 1976; pp 77–182.

    Google Scholar 

  8. Stone NN, Fair WR, Fishman J . Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. Prostate 1986; 9: 311–318.

    Article  CAS  PubMed  Google Scholar 

  9. Krieg M, Nass R, Tunn S . Effect of aging on endogenous level of 5a-hihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993; 77: 361–375.

    Google Scholar 

  10. Walsh PC, Wilson JD . The induction of prostatic hypertrophy in the dog with androstenediol. J Clin Invest 1976; 57: 1093–1097.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Collins AT, Zhiming B, Gilmore K, Neal DE . Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: oestrogen regulation of the androgen receptor. J Endocrinol 1994; 143: 269–277.

    Article  CAS  PubMed  Google Scholar 

  12. Deklerk DP, Coffey DS, Ewing LL, McDermott IR, Reiner WG, Robinson CH et al. Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest 1979; 64: 842–849.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Clement KM, Nanda J, Chapman KE, Habib FK . Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J Endocrinol 2008; 197: 483–491.

    Article  CAS  Google Scholar 

  14. Shapiro E, Steiner MS . Role of growth factors in prostatic development. In: Kirby R (ed) Textbook of Benign Prostatic Hyperplasia. ISIS Medical Media: Oxford, UK, 1996; pp 17–19.

    Google Scholar 

  15. Brolin J, Skoog L, Ekman P . Immunohistochemistry and biochemistry in detection of androgen, progesterone and estrogen receptors in benign and malignant human prostatic tissue. Prostate 1992; 20: 281–295.

    Article  CAS  PubMed  Google Scholar 

  16. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung I . Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996; 10: 1167–1177.

    CAS  PubMed  Google Scholar 

  17. Helguero LA, Faulds MH, Gustafsson JA, Haldosen LA . Estrogen receptors alpha (ERα) and beta (ERβ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005; 24: 6605–6616.

    Article  CAS  PubMed  Google Scholar 

  18. Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A et al. Inducible upregulation of oestrogen receptor-β1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 2005; 34: 553–566.

    Article  CAS  PubMed  Google Scholar 

  19. Treeck O, Lattrich C, Springwald A, Ortmann O . Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 2010; 120: 557–565.

    Article  CAS  PubMed  Google Scholar 

  20. Hodges-Gallagher L, Valentine C, Bader S, Kushner P . Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 2008; 109: 241–250.

    Article  CAS  PubMed  Google Scholar 

  21. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC . Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004; 64: 423–428.

    Article  CAS  PubMed  Google Scholar 

  22. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA . Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004; 101: 1566–1571.

    Article  CAS  PubMed  Google Scholar 

  23. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA . Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006; 66: 11207–11213.

    Article  CAS  PubMed  Google Scholar 

  24. Weryha G, Pascal-Vigneron V, Klein M, Leclère J . Selective estrogen receptor modulators. Curr Opin Rheumatol 1999; 11: 301–306.

    Article  CAS  PubMed  Google Scholar 

  25. Weihua Z, Lathe R, Warner M, Gustaffson JA . An endocrine pathway in the prostate.ERbeta.AR, 5 alpha androstane 3 beta, 17 beta-diol and CYP7BI, regulates prostate growth. Proc Natl Acad Sci USA 2002; 99: 13589–13594.

    Article  CAS  PubMed  Google Scholar 

  26. Mc person SJ, Ellem SJ, Simpson ER, Pachev V, Risbridger GP . Essential role for estrogen receptor beta in stromal- epithial regualation of prostatic hyperplasia. Encrinology 2007; 148: 566–574.

    Article  CAS  Google Scholar 

  27. Mc person SJ, Ellem SJ, Risbridger GP . Estrogen regulated development and differentiation of prostate. Differentiation 2008; 76: 660–670.

    Article  CAS  Google Scholar 

  28. Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA . Estrogen receptor beta ligands: recent advances and biomedical applications. Med Res Rev 2011; 31: 364–442.

    Article  CAS  PubMed  Google Scholar 

  29. Cassidy A . Potential risks and benefits of phytoestrogen-rich diets. Int J Vitam Nutr Res 2003; 73: 120–126.

    Article  PubMed  Google Scholar 

  30. Prins GS, Korach KS . The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008; 73: 233–244.

    Article  CAS  PubMed  Google Scholar 

  31. Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ et al. Induction of apoptosis in low grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 2002; 11: 1689–1696.

    CAS  PubMed  Google Scholar 

  32. Morton M, Turkes A, Denis L, Griffith K . Can dietary factors influence prostatic disease? BJU Int 1999; 84: 594–554.

    Google Scholar 

  33. Severson RK, Nomura AM, Grove JS, Stemmermann GN . A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989; 49: 1857–1860.

    CAS  PubMed  Google Scholar 

  34. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hämäläinen E, Hasegawa T et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991; 54: 1093–1100.

    Article  CAS  PubMed  Google Scholar 

  35. Jong FH, Oishi K, Hayes RB, Bogdanowicz JF, Raatgever JW, van der Maas PJ et al. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. Cancer Res 1991; 51: 3445–3450.

    PubMed  Google Scholar 

  36. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863–870.

    Article  CAS  Google Scholar 

  37. Mersereau JE, Levy N, Staub RE, Baggett S, Zogric T, Chow S et al. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol 2008; 283: 49–57.

    Article  CAS  PubMed  Google Scholar 

  38. Paruthiyil S, Cvoro A, Zhao X, Wu Z, Sui Y, Staub RE et al. Drug and cell type-specific regulation of genes with different classes of estrogen receptor β-selective agonists. PLoS ONE 2009; 4: e6271.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Yang R, Ma YX, Chen LF, Zhou Y, Yang ZP, Zhu Y et al. Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia. Asian J Androl 2010; 12: 735–743.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Eaton CL . Aetiology and pathogenesis of benign prostatic hyperplasia. Curr Opin Urol 2003; 13: 7–10.

    Article  PubMed  Google Scholar 

  41. Soulitzis N, Karyotis I, Delakas D, Spandidos DA . Expression analysis of peptide growth factors VEGF, FGF2, TGFBT, EGF, and IGF1 in prostate cancer and BPH. Int J Oncol 2006; 29: 305–314.

    CAS  PubMed  Google Scholar 

  42. Rana S, Sen R, Kalra R, Arora B, Sharma P, Gahlawat S . Immunhistochemical study of the expression of epidermal growth factor receptor in BPH, prostatic intraepithilial neoplasia and prostatic carcinoma. Indian J Pathol Microbiol 2006; 49: 495–499.

    PubMed  Google Scholar 

  43. Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C . Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon 10. Carcinogenesis 2004; 25: 237–240.

    Article  CAS  PubMed  Google Scholar 

  44. Lee KL, Peehl DM . Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004; 172: 1784–1791.

    Article  CAS  PubMed  Google Scholar 

  45. Kramer G, Marberger M . Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25–29.

    PubMed  Google Scholar 

  46. Kohnen PW, Drach GW . Patterns of inflammation in prostatic hyperplasia: a histologic and bacterial study. J Urol 1979; 121: 755–760.

    Article  CAS  PubMed  Google Scholar 

  47. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66: 96–107.

    CAS  PubMed  Google Scholar 

  48. Steiner G, Gessl A, Kramer G, Schollhammer A, Forster O, Marberger M . Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 1994; 151: 480–484.

    Article  CAS  PubMed  Google Scholar 

  49. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52: 43–48.

    Article  CAS  PubMed  Google Scholar 

  50. Yatkin E, Bernoulli J, Lammintausta R, Santti R . Fispemifene [Z-2-{2-[4-(4-chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol], a novel selective estrogen receptor modulator, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis. J Pharmacol Exp Ther 2008; 327: 58–67.

    Article  CAS  PubMed  Google Scholar 

  51. Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL . Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem 1992; 43: 557–564.

    Article  CAS  Google Scholar 

  52. Masumori N, Tsukamoto T, Kumamoto Y, Miyake H, Rhodes T, Girman GJ et al. Japanese men have smaller prostate volume but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol 1996; 155: 1324–1327.

    Article  CAS  PubMed  Google Scholar 

  53. Fujikawa S, Matsuura H, Kanai M, Fumino M, Ishii K, Arima K et al. Natural history of human prostate gland: morphometric and histopathological analysis of Japanese men. Prostate 2006; 65: 355–364.

    Article  Google Scholar 

  54. McPherson S, Hussaina S, Balanathana P, Hedwardsa S, Niranjana B, Granta M et al. Estrogen receptor–β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated. PNAS 2010; 107: 3123–3128.

    Article  CAS  PubMed  Google Scholar 

  55. Glienke W, Dolgova Y, Müller I, Grösch S, Binder J, Geisslinger G et al. Induction of apoptosis in human prostate stromal cells by 4-hydroxytamoxifen: an alternative therapy for benign prostate hyperplasia. World J Urol 2004; 22: 452–456.

    Article  CAS  PubMed  Google Scholar 

  56. Hayward SW, Rosen MA, Cunha GR . Stromal-epithelial interactions in the normal and neoplastic prostate. Br J Urol 1997; 79: 18–26.

    Article  PubMed  Google Scholar 

  57. Rijken AM, Hu J, Perlman EJ, Morsberger LA, Long P, Kern SE et al. Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosomes Cancer 1999; 26: 185–191.

    Article  CAS  PubMed  Google Scholar 

  58. Norman BH, Dodge JA, Richardson TI, Borromeo PS, Lugar CW, Jones SA et al. Benzopyrans are selective estrogen receptor β agonists with novel activity in models of benign prostatic hyperplasia. J Med Chem 2006; 49: 6155–6157.

    Article  CAS  PubMed  Google Scholar 

  59. Wilson D . The pathogenesis of bellign prostatic hyperplasia. Am Med 1980; 68: 745.

    Article  CAS  Google Scholar 

  60. McNeal E . Origin and evolution of benign prostatic enlargement. Invest. Urol 1978; 5: 340.

    Google Scholar 

  61. Lawson RK . Etiology of benign prostatic hyperplasia. In Lepoy, Hand Lawson, RK (eds) Prostatic diseases. W:B. Sallnders: Philadelphia, PA, USA., Ch. 7 1993; pp 89–95.

    Google Scholar 

  62. Isaac JT, Coffey DS . Etiology and disease process of benign prostatic hypelplasia. Prostate Suppl 1989; 2: 33.

    Article  Google Scholar 

  63. Hu WY, Shi GB, Lam HM, Hu DP, Ho SM, Madueke IC et al. Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells. Endocrinology 2011; 152: 2150–2163.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Ho CK, Habib FK . Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol 2011; 8: 29–41.

    Article  CAS  PubMed  Google Scholar 

  65. Risbridger GP, Frydenberg M, Hayward SW, Clark PE, Appu S . Endocrinology of the prostate. In Groot LJD (ed), 6th edn 2010.

  66. Ellem SJ, Risbridger GP . Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 2007; 7: 621–627.

    Article  CAS  PubMed  Google Scholar 

  67. Shanle ER, Xu W . Selectively targeting estrogen receptors for cancer treatment. Adv Drug Deliv Rev 2010; 62: 1265–1276.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Matthews J, Gustafsson JA . Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 2003; 3: 281–292.

    Article  CAS  PubMed  Google Scholar 

  69. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF . A variant of estrogen receptor-, hER- 36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 2006; 103: 9063–9068.

    Article  CAS  PubMed  Google Scholar 

  70. Levin ER . Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol 2001; 91: 1860–1867.

    Article  CAS  PubMed  Google Scholar 

  71. Bjornstrom L, Sjoberg M . Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005; 19: 833–842.

    Article  CAS  Google Scholar 

  72. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA . Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925–5930.

    Article  CAS  PubMed  Google Scholar 

  73. Mewshaw RE, Edsall RJ, Yang C, Manas ES . ERβ ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERβ selectivity. J Med Chem 2005; 48: 3953–3979.

    Article  CAS  PubMed  Google Scholar 

  74. Neubauer BL, McNulty AM, Chedid M, Chen K, Goode RL, Johnson MA et al. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model. Cancer Res 2003; 63: 6056–6062.

    CAS  PubMed  Google Scholar 

  75. Elloso MM, Phiel K, Henderson RA, Harris HA, Adelman SJ . Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. J Endocrinol 2005; 185: 243–252.

    Article  CAS  PubMed  Google Scholar 

  76. Davis DD, Díaz-Cruz ES, Landini S, Kim Y-W, Brueggemeier RW . Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells. J Steroid Biochem Mol Biol 2008; 108: 23–31.

    Article  CAS  PubMed  Google Scholar 

  77. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA . Estrogen receptor-b potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001; 44: 4230–4251.

    Article  CAS  PubMed  Google Scholar 

  78. Imamov O, Shim GJ, Warner M, Gustafsson JA . Estrogen receptor beta in health and disease. Biol Reprod 2005; 73: 866–871.

    Article  CAS  PubMed  Google Scholar 

  79. Zhou Y, Xiao XQ, Chen LF, Yang R, Shi JD, Du XL et al. Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats. Asian J Androl 2009; 11: 451–459.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Hong SG, Kim MK, Jang G, Oh HJ, Park JE, Kang JT et al. Generation of red fluorescent protein transgenic dogs. Genesis 2009; 47: 314–322.

    Article  CAS  PubMed  Google Scholar 

  81. Nicholson TM, Ricke EA, Marker PC, Miano JM, Mayer RD, Timms BG et al. Testosterone and 17β-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice. Endocrinology 2012; 153: 5556–5565.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Nomura H, Kawashima H, Masaki S, Hosono TY, Matsumura K, Tamada S et al. Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells. Prostate Cancer Prostatic Dis 2009; 12: 375–381.

    Article  CAS  PubMed  Google Scholar 

  83. Nicholson TM, Ricke WA . Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 2011; 82: 184–199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Corrada Y, Arias D, Rodriguez R, Spaini E, Fava F, Gobello C . Effect of tamoxifen citrate on reproductive parameters of male dogs. Theriogenology 2004; 61: 1327–1341.

    Article  CAS  PubMed  Google Scholar 

  85. Gonzalez G, Guendulain C, Maffrand C, Gobello C . Comparison of the effect of the aromatase inhibitor, anastrazole, to the antioestrogen, tamoxifen citrate, on canine prostate and semen. Reprod Domest Anim 2009; 44: 316–319.

    Article  PubMed  Google Scholar 

  86. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010; 184: 1316–1321.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Taneja SS, Morton R, Barnette G, Sieber P, Hancock ML, Steiner M . Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol 2013; 31: 523–529.

    Article  CAS  PubMed  Google Scholar 

  88. Smith MR, Malkowicz SB, Chu F, Forrest J, Sieber P, Barnette KG et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 2008; 26: 1824–1829.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, King George Medical University, Lucknow, India

    M Garg, D Dalela, D Dalela, A Goel, M Kumar & S N Sankhwar

  2. Division of Endocrinology, Central Drug Research Institute, Council of Scientific and Industrial Research, Lucknow, India

    G Gupta

Authors
  1. M Garg
    View author publications

    Search author on:PubMed Google Scholar

  2. D Dalela
    View author publications

    Search author on:PubMed Google Scholar

  3. D Dalela
    View author publications

    Search author on:PubMed Google Scholar

  4. A Goel
    View author publications

    Search author on:PubMed Google Scholar

  5. M Kumar
    View author publications

    Search author on:PubMed Google Scholar

  6. G Gupta
    View author publications

    Search author on:PubMed Google Scholar

  7. S N Sankhwar
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to M Garg.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garg, M., Dalela, D., Dalela, D. et al. Selective estrogen receptor modulators for BPH: new factors on the ground. Prostate Cancer Prostatic Dis 16, 226–232 (2013). https://doi.org/10.1038/pcan.2013.17

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/pcan.2013.17

Keywords

This article is cited by

Search

Advanced search

Quick links